ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Pittsburgh, PA, USA:

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor ...

Active, not recruiting
Recurrent Ovarian Carcinoma
Platinum-resistant Ovarian Cancer
Diagnostic Test: ChemoID Assay
Drug: Standard Chemotherapy

Phase 3

Cordgenics

Pittsburgh, Pennsylvania, United States and 7 other locations

using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian...

Enrolling
Recurrent Ovarian Cancer
Drug: CPI-0209
Drug: carboplatin

Phase 1

Lan Coffman

Pittsburgh, Pennsylvania, United States

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Pittsburgh, Pennsylvania, United States and 213 other locations

after frontline treatment with platinum-based therapy in advanced ovarian cancer patients with BRCAwt, homologous recombination def...

Enrolling
Ovarian Cancer
Drug: Olaparib tablet

Phase 2

Alexander B Olawaiye, MD

Pittsburgh, Pennsylvania, United States

the safety, tolerability, and anti-tumor activity of HCW9218 in combination with chemotherapy will be assessed in patients with advanced stage ovarian...

Enrolling
Ovarian Cancer
Drug: HCW9218
Drug: Carboplatin AUC 5 and paclitaxel

Phase 2

Haider Mahdi

Pittsburgh, Pennsylvania, United States

bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and prima...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Phase 3

Genelux

Pittsburgh, Pennsylvania, United States and 22 other locations

study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian...

Enrolling
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Talazoparib
Drug: ZEN003694

Phase 2

Haider Mahdi

Pittsburgh, Pennsylvania, United States

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Pittsburgh, Pennsylvania, United States and 31 other locations

IP rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP) for patients with recurrent platinum-sensitive ovarian...

Enrolling
Ovarian Cancer Recurrent
Drug: Cisplatin
Drug: Rintatolimod

Phase 1, Phase 2

Robert Edwards

Pittsburgh, Pennsylvania, United States

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...

Active, not recruiting
Recurrent Ovarian Cancer
Recurrent Primary Peritoneal Carcinoma
Drug: Relacorilant, 100mg QD
Drug: Relacorilant, 150mg QD

Phase 2

Corcept Therapeutics
Corcept Therapeutics

Pittsburgh, Pennsylvania, United States and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems